Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

Overview of attention for article published in Journal of Neuro-Oncology, December 2017

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 50 Dimensions

Readers on

mendeley: 39 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 356 followers.

#elderly #gliomas Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. https://t.co/qs4HgvLqir

Reply Repost Favourite

#pedcns #gbm Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. https://t.co/qs4HgvLqir

Reply Repost Favourite